Victoria Johnson

Stephen Cunnane, PhD, Research Center on Aging, Universite de Sherbrooke, discussed the ketogenic drink used in his recent study and the action of ketogenic diets.

Researchers from USC propose a direct neurotoxic effect of particulate matter smaller than 2.5 μm.

A new post hoc analysis following the HALO CM study that showed a reduction in headache days with use of fremanezumab.

In this interview, Patrick Landazuri, MD, discusses the validity of laser ablation as an option for epilepsy surgery.

Stephen Krieger, MD from the Icahn School of Medicine at Mount Sinai spoke about the phase 3 trial of nabiximols he will be investigating in MS.

Stephen Cunnane, PhD, Research Center on Aging, Universite de Sherbrooke, discussed the findings and implications of a recent study of the drink’s effects on patients with mild cognitive impairment.

Seelos Therapeutics will soon enroll patients in its phase 2b/3 trial of SLS-005 in amyotrophic lateral sclerosis.

Despite having independent association with a number of outcomes, SVD MRI features lacked prognostic value for patients with stroke.

In this interview, Patrick Landazuri, MD, shares an in-depth look at his investigations into the safety and efficacy of laser ablation.

Machine learning models analyze routine clinical variables to determine the risk of delayed ischemic stroke and other outcomes.

Sharon Hesterlee, PhD, the executive vice president and chief research officer at MDA spoke to the benefits of its new partnership with DNAnexus.

Recent studies of the CSF P-tau217 blood biomarker suggest it may help to simplify the diagnosis of Alzheimer disease.

NeurologyLive spoke with Julie Bernhardt, PhD, to learn more about her investigations into developing guidelines for very early mobilization for stroke treatment.

The findings of a prospective, multicenter study support the results of previous single center studies.

Researchers developed the biomarker in hopes of simplifying the recent MRPI 2.0 measurement for use in clinical practice.

The EXTEND and EPITHET trials selected patients by perfusion mismatch rather than the less sensitive noncontrast computed tomography, the findings providing reassurance of consistency for thrombolysis-induced reperfusion.

The drug joins Cerebryx as the second FDA-approved fosphenytoin for benzodiazepine-refractory status epilepticus.

A tertiary analysis of the AVERT study reveals divergent findings suggesting that mortality increases with VEM compared to usual care after restricting follow-up to 14 days.

CND Life Science’s Syn-One test marks the next step in synucleinopathy detection by offering a quick and minimally invasive procedure.

The researchers aim to fill the void of approved treatments for mild cognitive impairment, showing the potential of brain energy rescue strategies in this patient population.

Contrary to prior findings, no evidence was found to support a protective association between leisure activity and risk of dementia.

In the largest study of its kind to date, researchers at Indiana University attempt to elucidate previously inconclusive literature on antiseizure drugs, autism, and ADHD.